Probiotic Stability and Encapsulation: Formulation Guide

Probiotic stability is the retention of viable cells, counted in colony forming units (CFU), from the end of fermentation through drying, blending, compression, packaging, distribution, and gastrointestinal transit. It is a definitional requirement rather than a quality preference: the criteria that qualify a microorganism as a probiotic include that it is “alive in sufficient numbers in the product at an efficacious dose throughout shelf life” [2].

Encapsulation is the main engineering answer, and reported gains are large, with one 2026 review summarising improvements of up to roughly 100-fold through microencapsulation during drying [3]. The controlling storage variable is water activity, which should generally sit below 0.25 and, for freeze-dried powders, below about 0.15 [3,4]. Regulators set the target that formulation has to hit. Canada requires a minimum of 80 % of the labelled quantity at end of shelf life and does not accept gravimetric declaration [17]. Australia requires overage to be designed in at the start of manufacture and states that accelerated stability studies are unlikely to substantiate a probiotic medicine’s stability [19].

Table of Contents

• What Stability Means for a Probiotic Ingredient
• Where Viable Cells Are Lost Between Fermenter and Gut
• Water Activity and Glass Transition Set the Storage Limit
• Drying Route: Freeze Drying Versus Spray Drying
• Protectants: What Sugars, Proteins, and Polymers Contribute
• Encapsulation Technologies Compared
• What Encapsulation Buys in Gastric Acid and Bile
• Downstream Processing: Tableting, Gummies, and Baked Formats
• Spore-Forming Strains as an Alternative to Encapsulation
• CFU, AFU, and Why Two Valid Methods Disagree
• Regulatory Status by Region
• Quality Specification, Safety, and Supplier Evaluation
• Frequently Asked Questions
• Key Takeaways
• Sources

What Stability Means for a Probiotic Ingredient

A probiotic is defined as a live microorganism that, when administered in adequate amounts, confers a health benefit on the host [1]. Because the definition rests on viability, a probiotic that has lost its viable count is not an underperforming ingredient, it is outside the category. The criteria set out for qualifying a microorganism as a probiotic require that it be characterised to strain level, safe for its intended use, supported by human clinical evidence, and present alive in sufficient numbers at an efficacious dose throughout shelf life [2]. That last criterion is what turns the mechanisms by which probiotics act into a formulation constraint.

Two practical consequences follow for product developers. First, the number that matters is the count at expiry, not at manufacture, which makes the decay curve a design input rather than a stability-study output. Second, where viability cannot be held, the alternative is to change category rather than to accept the loss, since inanimate microbial preparations carry no CFU decay at all.

Where Viable Cells Are Lost Between Fermenter and Gut

Viability loss is not one event but a sequence of them, and the largest single loss is often not the one a formulator is watching. Drying stress, storage decay, mechanical damage during dosage-form manufacture, and gastrointestinal exposure each remove a distinct fraction, and they compound.

Table 1. Principal stress factors acting on live probiotic cells, by stage

Two points are worth drawing out of the table. Losses expressed as percentages during drying and losses expressed in log reductions during digestion are not comparable, and a formulation that survives drying well can still fail in the stomach. Strain identity also moves every one of these numbers, which is why process parameters transfer poorly between strains.

Water Activity and Glass Transition Set the Storage Limit

Two linked physical properties, water activity and the glass transition temperature of the protective matrix, govern how quickly a dried probiotic loses viable cells in the warehouse. Both belong on the specification.

The Water Activity Limits That Apply to Dried Probiotics

Water activity is the variable that most reliably predicts how a dried probiotic behaves over months rather than minutes, because suppressing residual molecular mobility suppresses the reactions that inactivate cells. The storage target is therefore stated as an upper bound on water activity rather than as a moisture percentage. Below approximately 0.25, microbial metabolism is largely suppressed, while survival rates tend to fall significantly once water activity exceeds about 0.33 [3]. A 24-month real-time study of commercial probiotic products at 25 °C ± 2 °C and 60 % relative humidity concluded that water activity should not exceed 0.2, and that the limit for freeze-dried formulations should sit below 0.15 [4].

That study also reported that the count of active fluorescent units decreased as water activity increased across every product tested, with total declines over 24 months of 0.12 log10 for a single-strain product, 0.16 log10 for a two-strain product, and 0.26 log10 for a multi-strain product [4]. Strain count appears to correlate with decay rate, which is a useful check on multi-strain formulations that assume the blend behaves like its most robust member.

Why Glass Transition Temperature Decides Whether a Matrix Protects

Glass transition temperature is the mechanistic partner to water activity, because a matrix held in the glassy state restricts molecular movement and slows degradation. In a spray-dried lactic acid bacterium powder, the wall-material formulation reached a glass transition temperature of 64.44 °C against 12.65 °C without wall materials, and absorbed 12.95 % of its initial weight in water over 7 days against 69.73 % for the unprotected powder [11]. A matrix whose glass transition sits below ambient temperature is not protecting anything during warehouse storage.

• Specify water activity, not only moisture content, on the finished-product specification.
• Treat packaging as part of the formulation: moisture ingress moves water activity, and water activity moves the decay rate.
• Confirm that the carrier system raises the glass transition temperature above the highest anticipated storage temperature, including distribution.

Drying Route: Freeze Drying Versus Spray Drying

The drying decision trades survival against throughput. Freeze drying is the gentler process and generally gives the higher survival, but it is a slow, energy-intensive batch operation that is difficult to run continuously. Spray drying is continuous and scalable, and imposes combined thermal and dehydration stress.

A direct head-to-head on Lactiplantibacillus plantarum BG24 quantified the gap. Across 13 experimental runs at inlet temperatures of 145 °C to 180 °C and outlet temperatures of 60 °C to 85 °C, optimised spray drying at an inlet of 150 °C and an outlet of 83 °C achieved 92.23 % viability, with a moisture content of 3.57 % and a water activity of 0.266. Freeze drying of the same strain gave 97.69 % survival at a moisture content of 5.10 % and a water activity of 0.189 [6]. Over 30 days of storage, freeze-dried samples lost about 1 % of cell counts against 3 % to 5 % for spray-dried samples [6].

Outlet temperature is generally the controlling spray-drying parameter, because it sets the temperature the particle actually reaches once evaporative cooling ends. Strain pretreatment offers a further lever that costs little in equipment: heat-shock preconditioning has been reported to raise survival by up to roughly 31-fold, and encapsulation applied during drying by up to roughly 100-fold [3]. Work on spray-drying a *Bifidobacterium* strain with inulin, alginate, and maltodextrin illustrates how carrier selection and process optimisation are treated as one decision rather than two.

Protectants: What Sugars, Proteins, and Polymers Contribute

Protectants fall into two groups. Low molecular weight protectants, including sucrose, glucose, lactose, mannose, trehalose, and sorbitol, are thought to substitute for water at the membrane surface and to help form the glassy matrix. High molecular weight protectants, including inulin, maltodextrin, starch, skim milk, and whey protein, mainly contribute matrix bulk and raise the glass transition temperature. Trehalose, lactose, and whey protein are among the agents commonly used to stabilise cell structures during freeze drying [3].

Carrier choice moves survival by a measurable margin rather than a marginal one. In the spray-drying study above, reconstituted skim milk used alone gave 93.16 % survival and outperformed skim milk supplemented with maltodextrin [6]. In encapsulated systems, wall material selection drives encapsulation efficiency directly, with reported efficiencies for one widely studied strain reaching 97.57 % for an inulin, pectin, and sodium alginate composite and 93.06 % for hemp seed protein isolate, against an average of about 83 % for common sodium alginate blends [9].

Protectant ranking does not transfer between strains or between processes, and the literature contains apparent contradictions that are best read this way. Where maltodextrin underperformed as a spray-drying carrier in the study above, work on lyoprotectant selection for a freeze-dried *Limosilactobacillus* strain found maltodextrin to be the better stabiliser for long-term storage at low temperature. Protectant screening therefore belongs in the development programme for each strain and each drying route, not in a platform specification.

Encapsulation Technologies Compared

Encapsulation places a physical barrier between the cell and its stressors, and the routes differ far more in scalability and particle size than in whether they work at all.

Table 2. Encapsulation routes for probiotics, with reported performance and practical constraints

Particle size is a design variable with measurable consequences, not a by-product. In alginate capsules produced by extrusion from 2 % sodium alginate across a range of 100 µm to 1,500 µm, calcium binding was higher in smaller capsules, at 0.58 g/g in 200 µm capsules against 0.39 g/g at 400 µm, which improved thermal stability, while bacterial loading fell from 2.4 × 10^8 to 0.8 × 10^7 CFU/g because internal capsule volume dropped roughly 30-fold [10]. Smaller capsules are more robust and carry fewer cells, so size selection is a direct trade between protection and payload.

Single wall materials are rarely enough on their own, which is why biopolymer hydrogel matrices combining alginate, chitosan, gelatin, or pectin are common in practice. Hybrid process chains that pair spray drying with fluidised-bed agglomeration and coating are the usual route to reaching both a storage-stable powder and an acid-resistant particle in one product.

What Encapsulation Buys in Gastric Acid and Bile

Gastrointestinal survival is where encapsulation shows its largest measured effects, because free cells face pH values well below their tolerance. After 3 h at pH 1, free cells fell to 1.43 log CFU/g while encapsulated cells retained 5.61 log CFU/g, and at pH 2 encapsulated cells retained 6.46 log CFU/g [7]. Coating adds a further increment on top of a gelled core: gastric survival of one L. plantarum strain was 75 % with bare emulsion beads and 84 % with chitosan-coated beads, against 38 % for free cells [8].

Bile exposure in the small intestine acts on the membrane rather than on protein structure, and it is the stress most often underestimated in development. Free-cell reduction has been reported at up to 5.94 log CFU/g against 3.47 log CFU/g for coated cells [8]. Alginate systems show comparable protection over a full transit simulation, retaining above 7.7 log CFU/mL after simulated gastric and intestinal digestion and markedly improving survival relative to free cells [10].

These figures come from static and dynamic in vitro digestion models, which standardise conditions but do not reproduce transit time, food matrix effects, or individual variation. In vitro survival data are best treated as a comparative screening tool between formulations rather than as a prediction of delivered dose.

Downstream Processing: Tableting, Gummies, and Baked Formats

Losses during dosage-form manufacture are frequently larger than losses during drying, and they are easy to miss because they occur after the ingredient has been released against specification. In tableting, viable cell counts decrease significantly as compression pressure rises, and the survival rate is highly dependent on the applied pressure. At a minimal applied pressure of 40 MPa, survival of Lacticaseibacillus rhamnosus GG was 89 % in lactose tablets and 58 % in xylitol tablets [12], which shows that excipient plasticity matters as much as the press setting.

Gummies and other high-moisture formats are the least forgiving. Free water in the matrix raises water activity above the range in which dried cells stay quiescent, and probiotics are hygroscopic enough to take up moisture from the confection during storage. Where water activity in the finished unit cannot be held near or below 0.25, a coated or matrix-protected ingredient is usually a requirement rather than an upgrade [3].

Heat-processed foods present the hardest case. Work on enriching bread with encapsulated probiotics notes that baking temperatures can cause a significant reduction in viability, which is why fluidised-bed coating and, more often, a change of organism are the routes that succeed in that application.

Spore-Forming Strains as an Alternative to Encapsulation

Where a format is thermally or hydrically hostile, strain selection can substitute for process engineering. Spore-forming Bacillus species survive as dormant endospores and therefore do not depend on a protective matrix for shelf stability. Bacillus coagulans MTCC 5856 showed the highest thermal resistance among the strains compared in one evaluation, with a reported D-value of 35.71 at 90 °C, and higher resistance to simulated gastric juice at pH 1.3, 1.5, and 2.0 than the Lactobacillus strains tested [14]. The same strain retained 88.94 % viability through flatbread cooking and 94.56 % through wheat noodle processing [14].

The trade is evidentiary rather than technical. Clinical evidence attaches to the strain rather than the genus, so a substitution made for stability reasons has to be re-checked against the claims the product intends to support, using the evidence base for the specific replacement strain.

CFU, AFU, and Why Two Valid Methods Disagree

Enumeration method is part of the stability specification, because two accepted methods do not return the same shelf life. Plate counting measures cultivability and is covered by ISO 20128 for Lactobacillus acidophilus and ISO 29981 or IDF 220:2010 for Bifidobacterium [2]. Flow cytometry measures membrane integrity, enzymatic activity, or membrane potential under ISO 19344 | IDF 232:2015, whose membrane-integrity protocol reports active fluorescent units (AFU) as the difference between total and damaged cells [15].

Table 3. Retention after 12 months by plate count and flow cytometry, multi-strain synbiotic [5]

The divergence widens with storage stress and is attributed to a subpopulation of cells that remain alive but are unable to form colonies [5]. The practical consequence is direct: a specification written in CFU and one written in AFU will not expire on the same date, and a product that fails a plate-count release limit may still pass a membrane-integrity limit. ISO 19344 does not perform taxonomic differentiation and can overestimate counts when other bacteria are present [15], so flow cytometry substitutes for plate counting only where strain identity is established separately. Name the method, the standard, and the acceptance limit together, or the number on the certificate of analysis is not interpretable.

Regulatory Status by Region

Regulators, not stability science, set the number a formulation has to hit, and the requirements differ enough to change the design.

Table 4. Regulatory treatment of probiotic viability and labelling, by region

United States and Canada

The United States position is narrower than it is often described. The draft guidance announces the agency’s intent to exercise enforcement discretion where a firm wishes to specify the amount of a live microbial in colony forming units “in addition to the currently required unit of measure (milligrams) in the Supplement Facts label” [16]. The milligram declaration remains mandatory, and because total mass includes non-viable cells, mass and viable count do not track each other over shelf life.

Canada is the strictest on the number itself. The probiotics monograph dated 24 April 2026 requires all individual strain quantities to be indicated in CFU per dosage unit, states that gravimetric or volumetric amounts are not acceptable, and requires stability measures ensuring that at least 80 % of the labelled quantity is present at end of shelf life [17]. It also grants encapsulation an explicit process consequence: the restrictions on combining the monograph with others do not apply where the probiotics are microencapsulated as enteric-coated pellets or granules, provided the encapsulation is impermeable in the presence of prebiotics or resistant to enzymatic degradation in the presence of enzymes [17].

European Union and Australia

In the European Union, the only relevant authorised claim covers live yoghurt cultures and lactose digestion, conditional on at least 10^8 CFU per gram of live starter cultures [18]. Several member states permit the term “probiotic” under national rules or mutual recognition, so market access is decided country by country rather than at Union level. Australia’s guidance for listed probiotic medicines defines overage as the quantity added at the start of manufacture beyond the claimed quantity, requires measurement error and shelf-life losses to be accounted for when setting it, and states that accelerated stability studies are unlikely to substantiate the stability of a probiotic medicine [19]. That last point removes the shortcut most other supplement categories rely on: real-time data are effectively required.

Quality Specification, Safety, and Supplier Evaluation

Identity to strain level is the defining quality requirement, because the clinical literature, the regulatory dossier, and the safety assessment all attach to the strain rather than the species [2]. Canada’s monograph makes the same point operational, requiring species identification, strain characterisation, quantification in CFU, and a complete assessment of virulence properties, including the antibiotic resistance profile, virulence factor production, and toxigenic activity [17]. The United States Pharmacopeia has developed probiotic ingredient monographs covering representatives of Lactobacillus, Bacillus, Streptococcus, and Bifidobacterium, specifying identity, enumeration, contaminant limits, and further quality parameters [20].

A workable finished-product specification for a live microbial ingredient names:

• Strain designation with its culture-collection accession number, not the species alone.
• Potency in CFU per dosage unit, with the enumeration method and its standard stated, plus AFU and its method where flow cytometry is used.
• Water activity and residual moisture, with limits rather than typical values.
• The standard contaminant panel, plus the virulence and antibiotic-resistance screening the destination market requires.
• The stability protocol, including whether real-time data exist at the intended storage condition.

The safety record of probiotic ingredients has been reviewed in support of compendial monograph development, and that body of work is the appropriate starting point for a supplier dossier review rather than strain-level marketing material [20]. Safety assessment is strain-specific for the same reason efficacy is, so a supplier change at species level is a change of ingredient, not a change of vendor.

Frequently Asked Questions

What water activity should a probiotic powder be held at?

Below approximately 0.25 for dried products generally, since microbial metabolism is largely suppressed at that level and survival tends to fall significantly above about 0.33 [3]. For freeze-dried formulations, a 24-month study of commercial products concluded the limit should sit below 0.15, and reported that active fluorescent unit counts fell as water activity rose in every product tested [4].

Does encapsulation replace refrigeration?

Not reliably. Encapsulation slows decay by restricting moisture, oxygen, and acid access, and alginate systems have maintained viability for 300 days at 10 °C [10], but storage temperature remains an independent variable. Freeze-dried powders lost about 1 % of cell counts over 30 days against 3 % to 5 % for spray-dried powders in a direct comparison [6].

Which encapsulation route is the most scalable?

Spray drying, which is continuous and already established at industrial volume, at the cost of thermal and dehydration stress on the cells. Electrospraying and microfluidic routes give mild conditions and precise particle control but run at flow rates on the order of microlitres per hour and carry high equipment costs, which is not yet suited to large-scale manufacture [8].

Why do CFU and AFU results diverge over shelf life?

Plate counting measures the ability to form colonies while flow cytometry under ISO 19344 measures membrane integrity, and cells can lose cultivability while retaining an intact membrane. After 12 months at 25 °C, one multi-strain product retained 61.5 % by CFU and 93.8 % by AFU [5]. The two methods therefore imply different expiry dates and should not be substituted for one another without a stated bridge.

How much overage is required?

No regulator publishes a fixed figure. Australia’s guidance requires overage to be set so the claimed quantity is maintained through shelf life, accounting for measurement error and known losses [19], and Canada requires at least 80 % of the labelled quantity at end of shelf life [17]. The practical method is to derive overage from real-time decay data at the intended storage condition, since accelerated studies are unlikely to substantiate a probiotic medicine’s stability [19].

Are spore-forming strains a substitute for encapsulation?

In thermally or hydrically hostile formats, often yes. Bacillus coagulans MTCC 5856 showed a reported D-value of 35.71 at 90 °C and retained 88.94 % viability through flatbread cooking [14]. The trade is that clinical evidence attaches to the individual strain, so the substitution has to be re-checked against the claims the product intends to support.

Key Takeaways

• Probiotic stability is definitional rather than optional: the qualifying criteria require the strain to be alive in sufficient numbers at an efficacious dose throughout shelf life.
• Water activity is the controlling storage variable, with a general working limit below 0.25 and a freeze-dried limit below about 0.15 .
• Freeze drying typically gives higher survival than spray drying, 97.69 % against 92.23 % for one strain, while spray drying remains the scalable route .
• Encapsulation gains are largest in the gastrointestinal phase, where free cells fell to 1.43 log CFU/g at pH 1 against 5.61 log CFU/g encapsulated.
• Losses during tableting are frequently underestimated, with survival at 40 MPa reported at 89 % in lactose tablets and 58 % in xylitol tablets .
• Plate count and flow cytometry return different shelf lives, at 61.5 % against 93.8 % retention after 12 months at 25 °C in one product, so the specification must name the method.
• Canada requires at least 80 % of the labelled quantity at end of shelf life, and Australia requires designed-in overage supported by real-time rather than accelerated data .

Sources

1. Hill C, Guarner F, Reid G, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology, 2014;11:506-514. https://www.nature.com/articles/nrgastro.2014.66 (accessed 2026-08-29).
2. Binda S, Hill C, Johansen E, et al. Criteria to Qualify Microorganisms as “Probiotic” in Foods and Dietary Supplements. Frontiers in Microbiology, 2020;11:1662. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2020.01662/full (accessed 2026-08-29).
3. Kim H, Haque MA, Razzak MA, Jang MJ, Song S, Ku S. Probiotic Development Strategy Centered on Stability and Regulatory Considerations. Comprehensive Reviews in Food Science and Food Safety, 2026;25(1):e70320. https://ift.onlinelibrary.wiley.com/doi/full/10.1111/1541-4337.70320 (accessed 2026-08-29).
4. Sielatycka K, Śliwa-Dominiak J, Radaczyńska M, et al. Dynamics of Active Fluorescent Units (AFU) and Water Activity (aw) Changes in Probiotic Products, Pilot Study. Foods, 2023;12(21):4018. https://pmc.ncbi.nlm.nih.gov/articles/PMC10647652/ (accessed 2026-08-29).
5. Visciglia A, Allesina S, Amoruso A, De Prisco A, Dhir R, Bron PA, Pane M. Assessment of shelf-life and metabolic viability of a multi-strain synbiotic using standard and innovative enumeration technologies. Frontiers in Microbiology, 2022;13:989563. https://pmc.ncbi.nlm.nih.gov/articles/PMC9672074/ (accessed 2026-08-29).
6. Kaymak Ertekin F, Köprüalan Aydın Ö, Altay Ö. Enhancing Viability of Lactobacillus plantarum BG24 Through Optimized Spray Drying: Insights Into Process Parameters, Carrier Agents, Comparative Analysis With Freeze Drying, and Storage Condition Influences. Food Science & Nutrition, 2024;12:10330. https://pmc.ncbi.nlm.nih.gov/articles/PMC11666833/ (accessed 2026-08-29).
7. Arepally D, Reddy RS, Goswami TK. Studies on survivability, storage stability of encapsulated spray dried probiotic powder. Current Research in Food Science, 2020;3:235-242. https://pmc.ncbi.nlm.nih.gov/articles/PMC7575842/ (accessed 2026-08-29).
8. Zhu Y, Lv L, Du B, Zhao M. Next-Generation Microencapsulation Technologies for Probiotic Protection and Precision Delivery. Microbial Biotechnology, 2026;19:e70305. https://pmc.ncbi.nlm.nih.gov/articles/PMC12916023/ (accessed 2026-08-29).
9. León-Espinosa EB, Barrios-Francisco R, Colin-Molina A, Martínez-Palma NY, Rentería-Ortega M. Encapsulation and Functional Activity of Lactobacillus reuteri Strains: Advances, Challenges, and Perspectives. Comprehensive Reviews in Food Science and Food Safety, 2026;25:e70412. https://pmc.ncbi.nlm.nih.gov/articles/PMC12930331/ (accessed 2026-08-29).
10. Kurchenko V, Halavach T, Grigorian R, et al. Alginate microcapsule size modulates structural, thermal, and metabolic properties and gastrointestinal survival of encapsulated probiotic Lactiplantibacillus plantarum. npj Science of Food, 2026. https://www.nature.com/articles/s41538-026-01065-2 (accessed 2026-08-29).
11. Valle Vargas MF, Ruiz Pardo RY, Villamil-Díaz L, Alean J, Santagapita PR, Quintanilla-Carvajal MX. Encapsulation improves viability and stability of spray-dried Lactococcus lactis A12 for inclusion in fish feed. PLOS One, 2025;20(5):e0323000. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0323000 (accessed 2026-08-29).
12. Byl E, Bladt P, Lebeer S, Kiekens F. Importance of pressure plasticity during compression of probiotic tablet formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2019;145:7-11. https://pubmed.ncbi.nlm.nih.gov/31605741/ (accessed 2026-08-29).
13. Sibanda T, Marole TA, Thomashoff UL, Thantsha MS, Buys EM. Bifidobacterium species viability in dairy-based probiotic foods: challenges and innovative approaches for accurate viability determination and monitoring of probiotic functionality. Frontiers in Microbiology, 2024;15:1327010. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1327010/full (accessed 2026-08-29).
14. Majeed M, Majeed S, Arumugam S, Ali F, Beede K. Comparative evaluation for thermostability and gastrointestinal survival of probiotic Bacillus coagulans MTCC 5856. Bioscience, Biotechnology, and Biochemistry, 2021;85(4):962-971. https://academic.oup.com/bbb/article/85/4/962/6047178 (accessed 2026-08-29).
15. International Organization for Standardization. ISO 19344:2015 | IDF 232:2015. Milk and milk products, Starter cultures, probiotics and fermented products, Quantification of lactic acid bacteria by flow cytometry. https://www.iso.org/standard/64658.html (accessed 2026-08-29).
16. US Food and Drug Administration. Policy Regarding Quantitative Labeling of Dietary Supplements Containing Live Microbials; Draft Guidance for Industry; Availability. Federal Register, 7 September 2018, Docket FDA-2011-D-0376. https://www.federalregister.gov/documents/2018/09/07/2018-19367/policy-regarding-quantitative-labeling-of-dietary-supplements-containing-live-microbials-draft (accessed 2026-08-29).
17. Health Canada, Natural and Non-prescription Health Products Directorate. Probiotics monograph, 24 April 2026. https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=probio&lang=eng (accessed 2026-08-29).
18. European Commission. EU Register of nutrition and health claims made on foods, under Regulation (EC) No 1924/2006 and Commission Regulation (EU) No 432/2012. https://ec.europa.eu/food/food-feed-portal/screen/health-claims/eu-register (accessed 2026-08-29).
19. Therapeutic Goods Administration. Demonstrating the quality of listed probiotic medicines. https://www.tga.gov.au/resources/guidance/demonstrating-quality-listed-probiotic-medicines (accessed 2026-08-29).
20. Boyte ME, Akhtar N, Koshy B, Roe AL. A Review of Probiotic Ingredient Safety Supporting Monograph Development Conducted by the United States Pharmacopeia (USP). Journal of Dietary Supplements, 2024;22(1):123-161. https://pubmed.ncbi.nlm.nih.gov/38356247/ (accessed 2026-08-29).

Disclaimer

These statements have not been evaluated by the Food and Drug Administration. This information is provided for dietary supplement industry professionals and is not intended to diagnose, treat, cure, or prevent any disease.